'Trends in Pharmaceutical Deal Making 2009' is a must-have report for all involved in business development, marketing or competitive intelligence in understanding what lies behind such deals and how they come about.
In deal making, it can be hard to pick the optimum deal type for your situation. Even the most accomplished deal maker is unlikely to have been involved in each and every type of deal.
This indispensable report answers numerous key questions including:
- What is the rationale for different deal structures?
- What is the most relevant deal type to use in a particular situation?
- What are the key issues that must be considered for each deal type?
- How do I value these deals?
- What do these deals look like in real life?
- What is the impact of the economic downturn on deals?
The report analyses each type of deal in detail and, in addition, is supported by extensive analysis and case studies of real life examples from PharmaDeals® v2 Agreements and PharmaDeals Review.
|
- Introduction
- 1 Trends in Deal Making
- 1.1 Recent Trends
- 1.2 Deal Making by the Top 25 Pharmaceutical Companies
- 1.3 Biotechnology Company Perspective
- 1.4 Sector Trends
- 1.5 Changing Deals for Difficult Economic Times
- 2 Valuation Methods
- 2.1 Combining Methods
- 2.2 Why use eNPV and Benchmarking?
- 2.2.1 Benchmarking
- 2.2.2 Expected Net Present Value
- 2.2.3 Decision Trees
- 2.2.4 Sensitivity Analysis
- 2.2.5 Value Sharing
- 3 Simple Licensing Agreements
- 3.1 Simple License Definition
- 3.1.1 Rationale
- 3.1.2 PharmaDeals Analysis
- 3.2 Key Issues
- 3.2.1 Simple License
- 3.3 Licensing Case Study: Roche
- 3.4 Simple Licensing Case Study: S*BIO and Oynx
- 4 Collaborative R&D Agreements
- 4.1 Rationale
- 4.2 PharmaDeals Analysis
- 4.3 Case Study: Astex and Janssen
- 5 Evaluation Agreements
- 5.1 Rationale
- 5.2 PharmaDeals Analysis
- 5.3 Case Study: Ambrilia and ZBx
- 6 Technology Access Agreements
- 6.1 Rationale
- 6.2 PharmaDeals Analysis
- 6.3 Case Study: Alnylam and Takeda
- 7 Co-Marketing & Co-Promotion Agreements
- 7.1 Rationale
- 7.2 PharmaDeals Analysis
- 7.3 Key Issues
- 7.4 Case Study: Astellas and CoMentis
- 8 Marketing Agreements
- 8.1 Rationale
- 8.2 PharmaDeals Analysis
- 8.3 Case Study: Alkermes and Cilag
- 9 Product Sale and Purchase Agreements
- 9.1 Single Product Sale/Purchase
- 9.1.1 Rationale
- 9.2 PharmaDeals Analysis
- 9.3 Case Study: PDL BioPharma and EKR
- 10 Option Agreements
- 10.1 Option to Purchase
- 10.1.1 Rationale
- 10.2 PharmaDeals Analysis
- 10.3 Option to License
- 10.3.1 Rationale
- 10.4 PharmaDeals Analysis
- 10.5 Key Issues
- 10.5.1 License with Option to Purchase
- 10.6 Valuation Methods
- 10.6.1 License with Option to Purchase
- 10.7 Case Study: Ribomic and Archemix
- 11 Equity Investments
- 12 Alternate Deal Structures
- 12.1 Drug Royalty Companies
- 12.2 Risk Sharing Agreements with Contract Research Organisations
- 12.2.1 Case Study: Eli Lilly & Co
- 12.3 Quids
- 12.3.1 Rationale
- 12.3.2 PharmaDeals Analysis
- 13 Impact of the Credit Crunch and Future Trends
- 13.1 Deal Distributions
- 13.2 Deal Value Distributions
- 13.3 2009 and Beyond
- Figures
- 1 All Deals by Year
- 2 Product Deals Breakdown
- 3 Preclinical Deal Values by Year
- 4 Total Deal Values
- 5 Top 25 Pharmaceutical Companies: Deals versus Sales
- 6 Deal Intensity of the Top 10 Pharmaceutical Companies
- 7 Deal Intensity by Therapeutic Area
- 8 Deals by Territory
- 9 Integrated Valuation Methods
- 10 Hypothetical Deal Factors
- 11 Pharmaceutical Product Decision Tree
- 12 Approximate Deal Value Splits by Development Phase
- 13 All Licensing Deals By Year
- 14 Simple Licensing Deals by Year
- 15 Deal Values by Year
- 16 Licensing Deals by Development Phase and Year
- 17 Licensing Deals by Technology
- 18 Simple Licensing Deals by Technology
- 19 Territorial Distribution of Licensing Deals
- 20 Simple Licensing Deals by Therapeutic Area
- 21 R&D Collaboration Deals
- 22 Collaborative R&D Deals by Development Phase
- 23 Collaborative R&D Deals by Technology
- 24 Collaborative R&D Deals by Territory
- 25 Collaborative R&D Deal Values
- 26 Evaluation Agreements by Year
- 27 Evaluation Agreements by Development Phase
- 28 Evaluation Agreements by Technology
- 29 Evaluation Agreements by Territory
- 30 Evaluation Agreements by Value
- 31 Evaluation Agreements by Therapeutic Area
- 32 Technology Access Agreements by Year
- 33 Technology Access Agreements by Development Phase
- 34 Technology Access Agreements by Technology
- 35 Technology Access Agreements by Territory
- 36 Technology Access Agreements by Deal Value
- 37 Technology Access Agreements by Therapeutic Area
- 38 Total Co-Marketing & Co-Promotion Deals by Year
- 39 Co-Marketing & Co-Promotion Deals by Development Phase
- 40 Co-Marketing & Co-Promotion Deals by Technology
- 41 Co-Marketing & Co-Promotion Deals by Territory
- 42 Co-Marketing & Co-Promotion Deal Values
- 43 Marketing Agreements by Year
- 44 Marketing Agreements by Development Phase
- 45 Marketing Agreements by Technology
- 46 Marketing Agreements by Territory
- 47 Marketing Agreements Total Deal Value
- 48 Marketing Agreements by Therapeutic Area
- 49 Product Acquisitions by Year
- 50 Product Acquisitions by Development Phase
- 51 Product Acquisitions by Technology
- 52 Product Acquisition by Territory
- 53 Product Acquisition Total Deal Values
- 54 Product Acquisition by Therapeutic Area
- 55 Option to Purchase Deals by Year
- 56 Option to Purchase Deal Values
- 57 Option to Purchase Deals by Development Phase
- 58 Option to Purchase Deals by Technology
- 59 Option to Purchase Deals by Territory
Share this report
Other tasks Related Markets Manufacturing, Packaging & Detailing Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
